Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-li
about
Peripheral immune cell gene expression changes in advanced non-small cell lung cancer patients treated with first line combination chemotherapyMicroarray analysis of serum mRNA in patients with head and neck squamous cell carcinoma at whole-genome scaleSTAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients.Epidermal growth factor receptor inhibitors trigger a type I interferon response in human skin.Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistanceCross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cellsPrognostic value of amphiregulin and epiregulin mRNA expression in metastatic colorectal cancer patients.A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer.Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities.Effects of Cetuximab and Erlotinib on the behaviour of cancer stem cells in head and neck squamous cell carcinoma.
P2860
Q28394867-0AB62F7E-2E2C-4E81-B182-D9A193B280E6Q33597997-414FEF08-75D5-45E6-84FF-9218A73C0EFEQ35920773-26DAF6C7-49E3-455A-81C6-FCA6C86C30B6Q37565269-5D9D3ECD-6CCC-497A-A3F9-6755B44CF2F3Q38118934-3CAF983B-1B41-4A77-91AE-B96F03BF0868Q41978535-8E7902DD-9556-493D-95EA-287ECD601A5CQ42317498-98A633AA-0A76-43C0-BBE8-700B37E84CD6Q47158524-8711863C-B3C7-46F4-AA71-1DD059F6B461Q49843607-4E03F549-F0FF-4DDA-BF4A-FCE7C11CA34AQ55296915-8FB1E062-D7F6-418B-8600-9F24020979AF
P2860
Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-li
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Interferon/STAT1 and neureguli ...... etuximab-adapted tumor cell-li
@ast
Interferon/STAT1 and neureguli ...... etuximab-adapted tumor cell-li
@en
type
label
Interferon/STAT1 and neureguli ...... etuximab-adapted tumor cell-li
@ast
Interferon/STAT1 and neureguli ...... etuximab-adapted tumor cell-li
@en
prefLabel
Interferon/STAT1 and neureguli ...... etuximab-adapted tumor cell-li
@ast
Interferon/STAT1 and neureguli ...... etuximab-adapted tumor cell-li
@en
P2093
P50
P356
P1476
Interferon/STAT1 and neureguli ...... etuximab-adapted tumor cell-li
@en
P2093
Alejandro Vazquez-Martin
Bernardo Queralt
Cristina Oliveras-Ferraros
Eugeni Lopez-Bonet
Luciana Báez
Luis Bernadó
Manuel Adrados
Maria Carmen Pérez-Martínez
Rafael De Llorens
Raquel Guardeño
P304
P356
10.3892/IJO.2011.1155
P577
2011-08-09T00:00:00Z